Luteinizing Hormone-Releasing Hormone Agonists in the Treatment of Breast Cancer

Harvey, Harold A.

doi:10.1007/978-1-4613-1731-9_3

Cited by 5 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plasma levels of oestronc, androstenedione and testos terone are also reduced by LHRH analogue therapy [5,15]. The decreases arc not as dramatic as those seen for oestradiol and progesterone and, although equivalent levels to those determined in postmenopausal women during Zoladex therapy are produced (table I), they represent only a 10-30% fall in the circulating levels of these hormones.…”

Section: Endocrine Actions Of Lhrh Analogues In Premeno Pausal Women mentioning

confidence: 82%

“…Other arguments favouring such combined therapy in clude the possibility that they might reduce the risk of early tumour flare and shorten the time required to achieve a full suppression of ovarian activity [ 15]. Signifi cantly, our early endocrine studies in pre-and perimenopausal advanced breast cancer patients have not indi cated any adverse interactions between the two drugs.…”

Section: Discussionmentioning

confidence: 93%

“…Early studies examining the endocrinological actions of buserelin plus tamoxifen in premenopausal women, and which indicated no adverse interactions be tween the drugs when an adequate formulation of buserelin is used [26], are being clinically appraised in an EORTC randomised study. Combinations of leuprolide and tamoxifen are also under trial [15].…”

Section: Discussionmentioning

confidence: 99%

“…They include cessation of men struation, hot flushes and occasional nausea [11,12,16], effects in common with surgical oophorectomy [17], Within 2 months, all patients cease to have normal men strual periods, although spotting has been recorded in one study using daily injections of Zoladex [5], To date, increased pain soon after starting LHRH analogue ther apy has been reported in only 2/120 breast cancer patients and was not thought to be a true tumour flare [15].…”

Section: Side Effects Of Lhrh Analogue Therapymentioning

confidence: 99%

See 3 more Smart Citations

Review of the Endocrine Actions of Luteinising Hormone-Releasing Hormone Analogues in Premenopausal Women with Breast Cancer

Nicholson

Walker²,

Walker³

et al. 1989

Horm Res

View full text Add to dashboard Cite

The endocrinological actions of the luteinising hormone-releasing hormone (LHRH) analogue, Zoladex (goserelin) in premenopausal women with advanced breast cancer are reviewed. LHRH analogues are an interesting addition to the currently available treatments for hormone-sensitive breast cancer in premenopausal women. Their modest side effects and ease of administration are in contrast to the risks and morbidity of surgical endocrine therapy.

show abstract

Section: Endocrine Actions Of Lhrh Analogues In Premeno Pausal Women mentioning

confidence: 82%

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Side Effects Of Lhrh Analogue Therapymentioning

confidence: 99%

See 2 more Smart Citations

Review of the Endocrine Actions of Luteinising Hormone-Releasing Hormone Analogues in Premenopausal Women with Breast Cancer

Nicholson

Walker²,

Walker³

et al. 1989

Horm Res

View full text Add to dashboard Cite

show abstract

Use of LH-RH agonists in the treatment of breast disease

Nicholson

Walker

1989

Proc., Sect. B Biol. sci.

View full text Add to dashboard Cite

SynopsisThe effects of LH-RH agonists in advanced breast cancer patients are reviewed and compared to the efficacy of surgical ablation of the ovaries and X-ray induced menopause in the treatment of this disease. In both pre- and postmenopausal women, LH-RH agonists produce pituitary gland desensitisation and a fall in concentrations of LH and FSH. In premenopausal patients plasma progesterone and oestradiol levels fall to the castrate or postmenopausal range within three to four weeks. Tumour remissions have been observed in approximately 30% of premenopausal women (50% ER-positive) and approximately 10% of postmenopausal patients. The mechanism of action of LH-RH agonists is discussed and their current application to combined endocrine therapy, early breast cancer and mastalgia briefly outlined.

show abstract

Prevention of DMBA-induced rat mammary carcinomas comparing leuprolide, oophorectomy, and tamoxifen

Hollingsworth

Lerner

Lightfoot

et al. 1998

Breast Cancer Res Treat

View full text Add to dashboard Cite

Leuprolide, a gonadotropin releasing hormone agonist, is currently being evaluated in a pilot study of premenopausal women for the prevention of breast cancer. However, little data is available regarding the efficacy of leuprolide in experimental animal models of carcinoma when administered prior to the carcinogen. In the present study the capacity of leuprolide to prevent tumor development was evaluated by comparing its pretreatment effects in the DMBA-induced rat mammary carcinoma model to pretreatment with tamoxifen and oophorectomy. Fifty-five day old, female Sprague-Dawley rats were randomly allocated to one of four groups: 1) no treatment; 2) oophorectomy two weeks prior to DMBA; 3) leuprolide, 40 microg/kg/day; and 4) tamoxifen, 10 mg/kg/week. All animals received four 5 mg doses of DMBA for a total dose of 20 mg. Leuprolide and tamoxifen treatments began two weeks prior to DMBA and ended one week after DMBA administration. Animals were assessed weekly to determine palpable tumor onset, number, size, and volume. At the conclusion of the study (16 weeks), autopsies were performed and tumor tissue was collected for confirmation of malignancy. Seventy-eight percent of the untreated rats developed tumors. No tumors developed in the oophorectomy group, while the number of rats with tumors was significantly reduced (p<0.05) with both leuprolide (30%) and tamoxifen (21.9%) compared to controls (77.8%). There were no significant differences in the tumor number for each tumor-bearing rat or in tumor volume between treated and control groups. Using our dosage regimen, 'chemical oophorectomy' with leuprolide was not as effective as surgical oophorectomy in the prevention of chemical carcinogenesis by DMBA but was comparable to the results obtained with tamoxifen.

show abstract

Luteinizing Hormone-Releasing Hormone Agonists in the Treatment of Breast Cancer

Cited by 5 publications

References 18 publications

Review of the Endocrine Actions of Luteinising Hormone-Releasing Hormone Analogues in Premenopausal Women with Breast Cancer

Review of the Endocrine Actions of Luteinising Hormone-Releasing Hormone Analogues in Premenopausal Women with Breast Cancer

Use of LH-RH agonists in the treatment of breast disease

Prevention of DMBA-induced rat mammary carcinomas comparing leuprolide, oophorectomy, and tamoxifen

Contact Info

Product

Resources

About